Fate Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Fate Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-28.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 63% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 93%
Sales fell 93% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-93% / -55%In 3 years sales changed by -93% while total assets changed by -55%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-23.3×Operating cash was negative last year, while some debt falls due within a year.
Lower than 58% of Healthcare companies in United States.
Cash Cushion Ratio
+50%Cash, after subtracting all debt, equals 50% of its market value (net cash).
Higher than 77% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Fate Therapeutics, Inc. made a loss over the last year. Fate Therapeutics, Inc. owes $0.41 for every $1 it owns. Fate Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossFate Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.63The share price is 1.63 times Fate Therapeutics, Inc.'s book value per share, lower than 64% of Healthcare companies in United States.
Market cap
$250 MThe total market value of all of Fate Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 54% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$153 MWhat Fate Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.28Net worth divided by the number of shares. The share price of $2.09 is 1.6 times this, which is the P/B above.
Return on equity (ROE)
-60.8%Fate Therapeutics, Inc. lost 60.8% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
Owes vs Owns
0.41×Fate Therapeutics, Inc. owes $0.41 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Dividend yield
NoneFate Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
-51%Revenue fell 51% in the year to Dec 2025, and shrank 59% a year on average over 3 years.
Profit growth
LossFate Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-2051.1%Fate Therapeutics, Inc. lost $2051 for every $100 of revenue.
Cash vs debt
Net cashFate Therapeutics, Inc. held $126 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Fate Therapeutics, Inc.: $250 M ÷ $153 M (30 Jun 2026) = 1.6.
What is Fate Therapeutics, Inc.'s return on equity?
Fate Therapeutics, Inc. lost 60.8% of its shareholders' money over the last year, lower than 58% of Healthcare companies in United States.
How much does Fate Therapeutics, Inc. owe compared with what it owns?
Fate Therapeutics, Inc. owes $0.41 for every $1 it owns (low), lower than 51% of Healthcare companies in United States.
Does Fate Therapeutics, Inc. pay a dividend?
No. Fate Therapeutics, Inc. does not currently pay a dividend.
Is Fate Therapeutics, Inc.'s revenue growing?
Revenue fell 51% in the year to Dec 2025, and shrank 59% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.